Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
146.10
-0.28 (-0.19%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Neurocrine Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $206.22. The average 1-year stock price forecast is 41.15% higher than the current stock price, while the lowest is $150 (+2.67%) and the highest is $253 (+73.17%).
Price Target: $206.22 (+41.15%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 20 | 21 | 20 | 20 | 21 | 21 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 29 | 28 | 28 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Buy Reiterates $204 | Buy | Reiterates | $204 | +39.63% | Oct 16, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $200 | Buy | Maintains | $200 | +36.89% | Oct 13, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $187 | Buy | Maintains | $187 | +27.99% | Oct 13, 2026 |
| BMO Capital | BMO Capital | Hold Maintains $164 → $150 | Hold | Maintains | $164 → $150 | +2.67% | Oct 12, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $214 | Buy | Reiterates | $214 | +46.48% | Oct 9, 2026 |
Financial Forecast
Revenue This Year
3.90B
from 2.86B
Increased by 36.46%
Revenue Next Year
4.55B
from 3.90B
Increased by 16.69%
EPS This Year
10.27
from 6.39
Increased by 60.68%
EPS Next Year
11.97
from 10.27
Increased by 16.61%
EPS and Forward PE are based on non-GAAP adjusted numbers.